Jump to main content
Jump to site search


Fully automated, on-site isolation of cfDNA from whole blood for cancer therapy monitoring

Author affiliations

Abstract

The potential utility of circulating tumour DNA (ctDNA) in patient blood for cancer diagnostics and real-time monitoring of disease progression is highly recognized. However, the lack of automated and efficient methods for cell-free DNA (cfDNA) isolation from peripheral blood has remained a challenge for broader acceptance of liquid biopsy in general clinical settings. Here, we demonstrate a lab-on-a-disc system equipped with newly developed, electromagnetically actuated, and reversible diaphragm valves that allows fully automated and rapid (<30 min) isolation of cfDNA from whole blood (>3 ml) to achieve high detection sensitivity by minimizing the degradation of fragile ctDNA as well as contamination of wild-type DNA from abundant blood cells. As a proof of concept study, we used the lab-on-a-disc to isolate cfDNA from patients with non-small cell lung cancer and successfully detected epidermal growth factor receptor gene mutations (L858R, T790M) during targeted drug therapy. The proposed lab-on-a-disc enables a fully automated, rapid, and point-of-care cfDNA enrichment starting from whole blood to facilitate the wide use of liquid biopsy in routine clinical practice.

Graphical abstract: Fully automated, on-site isolation of cfDNA from whole blood for cancer therapy monitoring

Back to tab navigation

Supplementary files

Publication details

The article was received on 09 Feb 2018, accepted on 09 Apr 2018 and first published on 09 Apr 2018


Article type: Paper
DOI: 10.1039/C8LC00165K
Citation: Lab Chip, 2018, Advance Article
  •   Request permissions

    Fully automated, on-site isolation of cfDNA from whole blood for cancer therapy monitoring

    C. Kim, J. Park, V. Sunkara, T. Kim, Y. Lee, K. Lee, M. Kim and Y. Cho, Lab Chip, 2018, Advance Article , DOI: 10.1039/C8LC00165K

Search articles by author

Spotlight

Advertisements